Literature DB >> 9515662

Bacteriophages show promise as antimicrobial agents.

J Alisky1, K Iczkowski, A Rapoport, N Troitsky.   

Abstract

The emergence of antibiotic-resistant bacteria has prompted interest in alternatives to conventional drugs. One possible option is to use bacteriophages (phage) as antimicrobial agents. We have conducted a literature review of all Medline citations from 1966-1996 that dealt with the therapeutic use of phage. There were 27 papers from Poland, the Soviet Union, Britain and the U.S.A. The Polish and Soviets administered phage orally, topically or systemically to treat a wide variety of antibiotic-resistant pathogens in both adults and children. Infections included suppurative wound infections, gastroenteritis, sepsis, osteomyelitis, dermatitis, empyemas and pneumonia; pathogens included Staphylococcus, Streptococcus, Klebsiella, Escherichia, Proteus, Pseudomonas, Shigella and Salmonella spp. Overall, the Polish and Soviets reported success rates of 80-95% for phage therapy, with rare, reversible gastrointestinal or allergic side effects. However, efficacy of phage was determined almost exclusively by qualitative clinical assessment of patients, and details of dosages and clinical criteria were very sketchy. There were also six British reports describing controlled trials of phage in animal models (mice, guinea pigs and livestock), measuring survival rates and other objective criteria. All of the British studies raised phage against specific pathogens then used to create experimental infections. Demonstrable efficacy against Escherichia, Acinetobacter, Pseudomonas and Staphylococcus spp. was noted in these model systems. Two U.S. papers dealt with improving the bioavailability of phage. Phage is sequestered in the spleen and removed from circulation. This can be overcome by serial passage of phage through mice to isolate mutants that resist sequestration. In conclusion, bacteriophages may show promise for treating antibiotic resistant pathogens. To facilitate further progress, directions for future research are discussed and a directory of authors from the reviewed papers is provided.

Entities:  

Mesh:

Year:  1998        PMID: 9515662     DOI: 10.1016/s0163-4453(98)92874-2

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  70 in total

1.  The murky origin of Snow White and her T-even dwarfs.

Authors:  S T Abedon
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

Review 2.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.

Authors:  Alex R Hall; Daniel De Vos; Ville-Petri Friman; Jean-Paul Pirnay; Angus Buckling
Journal:  Appl Environ Microbiol       Date:  2012-06-01       Impact factor: 4.792

4.  Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections.

Authors:  Caroline Westwater; Laura M Kasman; David A Schofield; Phillip A Werner; Joseph W Dolan; Michael G Schmidt; James S Norris
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 5.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Phage-based biocontrol strategies to reduce foodborne pathogens in foods.

Authors:  Lawrence D Goodridge; Bledar Bisha
Journal:  Bacteriophage       Date:  2011-05-01

7.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Authors:  Ryohei Watanabe; Tetsuya Matsumoto; Go Sano; Yoshikazu Ishii; Kazuhiro Tateda; Yoshinobu Sumiyama; Jumpei Uchiyama; Shingo Sakurai; Shigenobu Matsuzaki; Shosuke Imai; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

9.  Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals.

Authors:  S O'Flaherty; R P Ross; W Meaney; G F Fitzgerald; M F Elbreki; A Coffey
Journal:  Appl Environ Microbiol       Date:  2005-04       Impact factor: 4.792

10.  Characterization of Salmonella bacteriophages isolated from swine lagoon effluent.

Authors:  Michael R McLaughlin; Rodney A King
Journal:  Curr Microbiol       Date:  2007-11-10       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.